Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942982 | 0.80 | HTT (0.41) | HTTCYP11B2 | |
| SCHEMBL3596885 | 0.80 | PTPN1 (0.41) | CA12CA1CA2CA9PTPN1 | |
| SCHEMBL4063463 | 0.72 | SLC6A2 (0.39) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4057197 | 0.72 | ALDH1A1 (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4065236 | 0.72 | ALDH1A1 (0.37) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4065561 | 0.72 | TDP1 (0.37) | ALDH1A1 | |
| SCHEMBL4063451 | 0.70 | SLC40A1 (0.39) | ALDH1A1PTPN1HTTSLC40A1 | |
| SCHEMBL4055064 | 0.68 | LMNA (0.39) | ALDH1A1HTT | |
| SCHEMBL3605818 | 0.68 | SLC6A2 (0.38) | ALDH1A1HTT | |
| SCHEMBL11525997 | 0.66 | KDM4E (0.55) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | CA12 3902/4885CA1 3794/4885CA2 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.